Abstract 63P
Background
Eribulin, a novel anti-tubulin agent, is a preferred treatment for patients (pts) with metastatic breast cancer (mBC) who have been pretreated with anthracycline and/or taxane-based therapy. Preclinical data suggest a potential synergistic effect of eribulin and platinum. However, clinical data on the combination for mBC are lacking. We evaluated eribulin plus platinum in pts with mBC.
Methods
This multi-center, real-world cohort study included pts with pre-treated metastatic triple- negative breast cancer (TNBC) or endocrine-refractory hormone receptor (HR) -positive, HER2 -negative mBC who received eribulin plus carboplatin (ErCb). Eribulin (1.4 mg/m2) and carboplatin (target AUC=2) were administered intravenously on days 1 and 8 of 21-day cycles. Progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR) and adverse events (AEs) were evaluated.
Results
From March 2022 to August 2023, 19 pts with TNBC and 11 with HR+HER2- mBC were included. Of the 19 pts with TNBC, 8 had an initial diagnosis of HR+HER2- disease. All 30 pts were female, with a median (range) age of 46 (31–60) years and had received a median of 2 (1–6) prior lines of therapy. Visceral metastases were present in 22 pts (73.3%). Best overall response, ORR, DCR, and PFS are shown in the table. Median overall survival was not reached. After a median of 6 cycles (range, 2–8) of ErCb, the most common grade 3–4 AEs were neutropenia (40.0%), leukopenia (23.3%), febrile neutropenia (10.0%), and anemia (3.3%). No grade 3–4 non-hematological AEs were observed. Table: 63P
| Patients, n (%) | |||
| Response | All patients (N=30) | TNBC group (N=19) | HR+HER2- group (N=11) |
| Complete response | 0 | 0 | 0 |
| Partial response | 19 (63.3) | 12 (63.2) | 7 (63.6) |
| Stable disease | 7 (23.3) | 4 (21.1) | 3 (27.3) |
| Progressive disease | 4 (13.3) | 3 (15.8) | 1 (9.1) |
| ORR | 19 (63.3) | 12 (63.2) | 7 (63.6) |
| DCR | 26 (86.6) | 16 (84.2) | 10 (91.0) |
| Median PFS, months (95% CI) | 5.0 (4.0-6.0) | 5.0 (1.3-8.7) | 5.6 (3.0-8.1) |
Conclusions
In this cohort of pts with heavily pre-treated HER2- mBC, ErCb demonstrated promising efficacy and a manageable safety profile. Further studies exploring this combination in earlier lines of treatment for mBC are warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
426P - Characterization of a novel comprehensive genomic profiling test with better detection of heterozygous deletions and gene fusions
Presenter: ryouta kakuta
Session: Poster Display
Resources:
Abstract
427P - Real-world performance of a comprehensive next-generation sequencing (NGS) panel for patients (pts) with solid tumors from Asia and the Middle East (AME)
Presenter: Nitesh Rohatgi
Session: Poster Display
Resources:
Abstract
428P - What do women want to see in a personalized breast cancer risk report? A qualitative study of Asian women of two countries
Presenter: Faustina Audrey Agatha
Session: Poster Display
Resources:
Abstract
429P - Clinical utility and outcomes of liquid biopsy-based next generation sequencing in identification of actionable genomic mutations in solid malignancy: A single center retrospective study in the Philippines
Presenter: Omar Maaño
Session: Poster Display
Resources:
Abstract
436P - Chemotherapy-induced hand-foot syndrome, comparative efficacy and safety of pharmacological prophylaxis: Systematic review and network meta-analysis
Presenter: Anand Srinivasan
Session: Poster Display
Resources:
Abstract
437P - A randomized single blinded phase II trial comparing efficacy and quality of life of topical aloe vera gel plus urea cream versus urea cream alone for prevention of hand-foot syndrome in cancer patients receiving capecitabine
Presenter: Lucksika Wanichtanom
Session: Poster Display
Resources:
Abstract
438P - A novel treatment for immune checkpoint inhibitor-related myocarditis
Presenter: Takahiro Niimura
Session: Poster Display
Resources:
Abstract
439P - Randomized controlled trial evaluating efficacy of topical urea-based cream for capecitabine-associated hand-foot syndrome prevention
Presenter: Concord Wongkraisri
Session: Poster Display
Resources:
Abstract
440P - Real-world adverse events of targeted therapy reported by pharmacist in oncology clinic
Presenter: TIKUMPORN PORNWISETSIRIKUL
Session: Poster Display
Resources:
Abstract
441P - The prophylactic efficacy of telpegfilgrastim, a Y-shape branched pegylated G-CSF in patient with chemotherapy-induced neutropenia: A multicenter, randomized phase III study
Presenter: Xinshuai Wang
Session: Poster Display
Resources:
Abstract